Skip to main content
Premium Trial:

Request an Annual Quote

Now Testing One for Flu

Moderna has launched a trial of an mRNA-based vaccine for seasonal influenza, according to the Verge.

Ars Technica adds that the candidate vaccine, called mRNA-1010, targets four influenza lineages similar to current flu vaccines. According to Moderna, the vaccine targets the lineages recommend by the World Health Organization: the seasonal influenza A lineages H1N1 and H3N2 as well as the influenza B lineages Yamagata and Victoria.

The Phase 1/2 randomized is to enroll about 180 participants to gauge the safety, reactogenicity, and immunogenicity of the candidate flu vaccine, the company adds. Eventually, Moderna hopes to bundle it with other vaccines for diseases like respiratory syncytial virus and human metapneumovirus and possibly SARS-CoV-2, according to Ars Technica.

"Our vision is to develop an mRNA combination vaccine so that people can get one shot each fall for high efficacy protection against the most problematic respiratory viruses," Stéphane Bancel, CEO of Moderna, says in a statement.

The Verge notes that Sanofi and Translate Bio have also begun a trial of an mRNA-based flu vaccine and that Pfizer and BioNTech are interested in one, too.

The Scan

Purnell Choppin Dies

Purnell Choppin, a virologist who led the Howard Hughes Medical Institute, has died at 91, according to the Washington Post.

Effectiveness May Decline, Data From Israel Suggests

The New York Times reports that new Israeli data suggests a decline in Pfizer-BioNTech SARS-CoV-2 vaccine effectiveness against Delta variant infection, though protection against severe disease remains high.

To See Future Risk

Slate looks into the use of polygenic risk scores in embryo screening.

PLOS Papers on Methicillin-Resistant Staphylococcus, Bone Marrow Smear Sequencing, More

In PLOS this week: genomic analysis of methicillin-resistant Staphylococcus pseudintermedius, archived bone marrow sequencing, and more.